PMV Pharma (NASDAQ:PMVP) Bolsa

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.

PMV Pharmaceuticals Inc

TD Securities analyst Andrew Charles maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Buy and raises the price target from $490 to $510.

News

Price Target

Analyst Ratings

TD Securities Maintains Buy on Domino's Pizza, Raises Price Target to $510

Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.32 by 15.62 percent. This is a 437.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $221.43 million which beat the analyst consensus estimate of $212.40 million by 4.25 percent. This is a 8.72 percent increase over sales of $203.66 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

DESP

Despegar.com Q4 Adj. EPS $0.27 Misses $0.32 Estimate, Sales $221.43M Beat $212.40M Estimate

General

Quhuo Posts 2H Revenue Of $423.97M And Adjusted EBITDA $1.26M

Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 50 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $76.26 million which beat the analyst consensus estimate of $52.71 million by 44.67 percent.

VRNA

Correction://Verona Pharma Q1 GAAP Earning per ADS $(0.16) Misses $(0.12) Estimate, Sales $76.26M Beat $52.71M Estimate

Guidance

Polaris Sees Q2 FY25 Sales Guidance Of $1.6B-$1.8B

WIIM

SANM

Sanmina shares are trading lower after the company reported Q2 financial results and issued Q3 guidance below estimates.

NXPI

NXP Semiconductors shares are trading lower after the company reported Q1 financial results and issued Q2 EPS guidance with its midpoint below estimates. The company announced CEO Kurt Sievers will retire at the end of 2025.

Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $76.26 million which beat the analyst consensus estimate of $52.71 million by 44.67 percent.

Verona Pharma Q1 GAAP Earning per ADS $(0.19) Misses $(0.12) Estimate, Sales $76.26M Beat $52.71M Estimate

UCTT

Ultra Clean Holdings shares are trading lower after the company reported worse-than-expected Q1 financial result and issued Q2 guidance below estimates.

Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) reported quarterly earnings of $0.64 per share which missed the analyst consensus estimate of $0.72 by 11.11 percent. This is a 3.03 percent decrease over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $15.42 billion which beat the analyst consensus estimate of $14.05 billion by 9.73 percent. This is a 4.45 percent increase over sales of $14.76 billion the same period last year.

Enterprise Prods Partners Q1 EPS $0.64 Misses $0.72 Estimate, Sales $15.42B Beat $14.05B Estimate

BYON

Beyond shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

TVGN

Tevogen Bio Holdings shares are trading higher after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.

OKTA

Okta shares are trading higher after the company announced it will replace Berry Global Group in the S&P Midcap 400, effective before the opening of trading on Thursday, May 1.

MGRM

AI Robotic Company Monogram Obtains Regulatory Approval From India's Central Drugs Standard Control Organization To Import mBôs TKA System To Conduct Clinical Trials

Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.54 by 7.41 percent. This is a 15.25 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $732.00 million which missed the analyst consensus estimate of $777.10 million by 5.80 percent. This is a 4.42 percent increase over sales of $701.00 million the same period last year.

ARCC

Ares Capital Q1 Adj. EPS $0.50 Misses $0.54 Estimate, Sales $732.00M Miss $777.10M Estimate

ABEO

Abeona Therapeutics shares are trading higher after the company announced FDA approval of ZEVASKYN for treating wounds in patients with recessive dystrophic epidermolysis bullosa.

JOBY

Joby Aviation Completes Flights With A Full Transition From Vertical To Cruise Flight And Back Again With A Pilot Onboard

Polaris Is Withdrawing Full Year 2025 Guidance Due To Trade And Economic Uncertainty

Offerings

BSGM

BioSig Technologies Issued 2.75M Restricted Shares to Service Providers for Business Development Services

<ul>
<li>ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure.</li>
<li>Approval based on the pivotal Phase 3 VIITAL study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile.</li>
<li>ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025.</li>
<li>Abeona Assist patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN.</li>
<li>Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA</li>
</ul>

Biotech

Health Care

The FDA Approves Abeona Therapeutics' Zevaskyn (Prademagene Zamikeracel) Gene-modified Cellular Sheets, Also Known As Pz-cel, As The First And Only Autologous Cell-based Gene Therapy For Wounds In Adult And Pediatric Patients With Recessive Dystrophic Epidermolysis Bullosa

Comments

PMV Pharma

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL